Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRINK: Pembrolizumab and SBRT Before Neoadjuvant Chemotherapy in Breast Cancer
NCT07188246Phase 2Recruiting
- Start
- Jan 2026
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in breast cancer. Primary endpoint: Pathological Complete Response at 6 months. Started Jan 2026; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07188246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07188246.